These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
850 related articles for article (PubMed ID: 24438679)
21. Early virologic response and IL28B polymorphisms in patients with chronic hepatitis C genotype 3 treated with peginterferon alfa-2a and ribavirin. Scherzer TM; Hofer H; Staettermayer AF; Rutter K; Beinhardt S; Steindl-Munda P; Kerschner H; Kessler HH; Ferenci P J Hepatol; 2011 May; 54(5):866-71. PubMed ID: 21145807 [TBL] [Abstract][Full Text] [Related]
22. The IL28B effect on hepatitis C virus kinetics among HIV patients after the first weeks of pegylated-interferon/ribavirin treatment varies according to hepatitis C virus-1 subtype. Rivero-Juarez A; Lopez-Cortes LF; Camacho A; Caruz A; Torres-Cornejo A; Martinez-Dueñas L; Ruiz-Valderas R; Torre-Cisneros J; Gutierrez-Valencia A; Rivero A AIDS; 2013 Jul; 27(12):1941-7. PubMed ID: 23917425 [TBL] [Abstract][Full Text] [Related]
23. HCV substitutions and IL28B polymorphisms on outcome of peg-interferon plus ribavirin combination therapy. Hayes CN; Kobayashi M; Akuta N; Suzuki F; Kumada H; Abe H; Miki D; Imamura M; Ochi H; Kamatani N; Nakamura Y; Chayama K Gut; 2011 Feb; 60(2):261-7. PubMed ID: 21068134 [TBL] [Abstract][Full Text] [Related]
24. [Association of interleukin 28B polymorphisms with response to pegylatedinterferon plus ribavirin therapy for chronic hepatitis C]. Xu H; Guo LL; He LL; Chen Y; Liu K; Lei BJ; Lei XZ Sichuan Da Xue Xue Bao Yi Xue Ban; 2012 Nov; 43(6):855-9. PubMed ID: 23387213 [TBL] [Abstract][Full Text] [Related]
25. Peginterferon alfa and ribavirin for chronic hepatitis C in patients eligible for shortened treatment, re-treatment or in HCV/HIV co-infection: a systematic review and economic evaluation. Hartwell D; Jones J; Baxter L; Shepherd J Health Technol Assess; 2011 Apr; 15(17):i-xii, 1-210. PubMed ID: 21473834 [TBL] [Abstract][Full Text] [Related]
26. Comparison of high ribavirin induction versus standard ribavirin dosing, plus peginterferon-α for the treatment of chronic hepatitis C in HIV-infected patients: the PERICO trial. Labarga P; Barreiro P; da Silva A; Guardiola JM; Rubio R; Aguirrebengoa K; Miralles P; Portu J; Téllez MJ; Morano L; Castro A; Pineda JA; Terrón A; Hernández-Quero J; Mariño A; Ríos MJ; Echeverría S; Asensi V; Vispo E; Soriano V; J Infect Dis; 2012 Sep; 206(6):961-8. PubMed ID: 22807523 [TBL] [Abstract][Full Text] [Related]
27. Role of interleukin 28B-related gene polymorphisms in chronic hepatitis C and the response to antiviral therapy in Koreans. Jung YK; Kim JH; Ahn SM; Yang JW; Park SJ; Kim JW; Yeon JE; Kwon OS; Kim YS; Choi DJ; Kim JH; Byun KS J Clin Gastroenterol; 2013 Aug; 47(7):644-50. PubMed ID: 23442843 [TBL] [Abstract][Full Text] [Related]
28. Test of IL28B polymorphisms in chronic hepatitis C patients treated with PegIFN and ribavirin depends on HCV genotypes: results from a meta-analysis. Jia Z; Ding Y; Tian S; Niu J; Jiang J PLoS One; 2012; 7(9):e45698. PubMed ID: 23029188 [TBL] [Abstract][Full Text] [Related]
29. Prediction of response to pegylated interferon plus ribavirin by IL28B gene variation in patients coinfected with HIV and hepatitis C virus. Pineda JA; Caruz A; Rivero A; Neukam K; Salas I; Camacho A; Palomares JC; Mira JA; Martínez A; Roldán C; de la Torre J; Macías J Clin Infect Dis; 2010 Oct; 51(7):788-95. PubMed ID: 20804372 [TBL] [Abstract][Full Text] [Related]
30. Antiviral regimen complexity index as an independent predictor of sustained virologic response in patients with chronic hepatitis C. Galán RJ; Cidoncha EC; Martin MF; Rodriguez CC; Almeida CV; Verdugo RM J Manag Care Pharm; 2013; 19(6):448-53. PubMed ID: 23806058 [TBL] [Abstract][Full Text] [Related]
31. Insulin resistance predicts sustained virological response to treatment of chronic hepatitis C independently of the IL28b rs12979860 polymorphism. Del Campo JA; Ampuero J; Rojas L; Conde M; Rojas A; Maraver M; Millán R; García-Valdecasas M; García-Lozano JR; González-Escribano MF; Romero-Gómez M Aliment Pharmacol Ther; 2013 Jan; 37(1):74-80. PubMed ID: 23121166 [TBL] [Abstract][Full Text] [Related]
32. Real life experience in treatment of HIV-1/HCV-coinfected patients with pegylated interferon alpha and ribavirin: predictors of SVR. Bruno G; Fasano M; Saracino A; Volpe A; Bartolomeo N; Ladisa N; Maggi P; Monno L; Angarano G New Microbiol; 2015 Jan; 38(1):21-7. PubMed ID: 25742144 [TBL] [Abstract][Full Text] [Related]
33. Interleukin 28B genetic polymorphisms and viral factors help identify HCV genotype-1 patients who benefit from 24-week pegylated interferon plus ribavirin therapy. Liu CH; Liang CC; Liu CJ; Tseng TC; Lin CL; Yang SS; Su TH; Hsu SJ; Lin JW; Chen JH; Chen PJ; Chen DS; Kao JH Antivir Ther; 2012; 17(3):477-84. PubMed ID: 22301466 [TBL] [Abstract][Full Text] [Related]
34. Meta-analysis: IL28B polymorphisms predict sustained viral response in HCV patients treated with pegylated interferon-α and ribavirin. Chen Y; Xu HX; Wang LJ; Liu XX; Mahato RI; Zhao YR Aliment Pharmacol Ther; 2012 Jul; 36(2):91-103. PubMed ID: 22591106 [TBL] [Abstract][Full Text] [Related]
35. IL28B and IL10R -1087 polymorphisms are protective for chronic genotype 1 HCV infection and predictors of response to interferon-based therapy in an East-Central European cohort. Pár A; Pár G; Tornai I; Szalay F; Várszegi D; Fráter E; Papp M; Lengyel G; Fehér J; Varga M; Gervain J; Schuller J; Nemes Z; Péterfi Z; Tusnádi A; Hunyady B; Haragh A; Szinku Z; Vincze A; Szereday L; Kisfali P; Melegh B BMC Res Notes; 2014 Jan; 7():12. PubMed ID: 24398031 [TBL] [Abstract][Full Text] [Related]
36. Interferon-λ3 polymorphisms in pegylated-interferon-α plus ribavirin therapy for genotype-2 chronic hepatitis C. Ishiguro H; Abe H; Seki N; Sugita T; Aida Y; Itagaki M; Sutoh S; Shimada N; Furihata T; Tsubota A; Aizawa Y World J Gastroenterol; 2015 Apr; 21(13):3904-11. PubMed ID: 25852275 [TBL] [Abstract][Full Text] [Related]
37. Peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a monotherapy in early virological responders and peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a, ribavirin and amantadine triple therapy in early virological nonresponders: the SMIEC II trial in naïve patients with chronic hepatitis C. Angelico M; Koehler-Horst B; Piccolo P; Angelico F; Gentile S; Francioso S; Tarquini P; Vecchia RD; Ponti L; Pilleri G; Barlattani A; Grieco A; Soccorsi F; Guarascio P; Demelia L; Sorbello O; Rossi Z; Forlini G; Zaru S; Bandiera F; Eur J Gastroenterol Hepatol; 2008 Jul; 20(7):680-7. PubMed ID: 18679072 [TBL] [Abstract][Full Text] [Related]
38. Role of IL28B genotyping in patients with hepatitis C virus-associated mixed cryoglobulinemia and response to PEG-IFN and ribavirin treatment. Boglione L; Cusato J; Allegra S; Cariti G; Di Perri G; D'Avolio A Arch Virol; 2015 Aug; 160(8):2009-17. PubMed ID: 26060059 [TBL] [Abstract][Full Text] [Related]
39. Ribavirin Concentrations Do Not Predict Sustained Virological Response in HIV/HCV-Coinfected Patients Treated with Ribavirin and Pegylated Interferon in the Swiss HIV Cohort Study. Kovari H; Russmann S; Ledergerber B; Müller D; Rotger M; Velli P; Cavassini M; Ambrosioni J; Bregenzer A; Stöckle M; Bernasconi E; Rauch A; Speck RF; PLoS One; 2015; 10(7):e0133879. PubMed ID: 26218843 [TBL] [Abstract][Full Text] [Related]
40. Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in HIV/hepatitis C virus-coinfected patients. Rallón NI; Naggie S; Benito JM; Medrano J; Restrepo C; Goldstein D; Shianna KV; Vispo E; Thompson A; McHutchison J; Soriano V AIDS; 2010 May; 24(8):F23-9. PubMed ID: 20389235 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]